Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.
Maxim Group Downgrades Aridis Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.
Related Posts
Inspira Technologies Is Developing The VORTX Blood Oxygenator, A Unique Technology For Saturating Blood With Oxygen And Removing Carbon Dioxide
Total addressable market is currently estimated at $1.16 billion
RA'ANANA, Israel, May 11, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW)
Analyst Ratings for Nuvei
Analysts have provided the following ratings for Nuvei (NASDAQ:NVEI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Stifel Maintains Hold on Watts Water Technologies, Lowers Price Target to $130
Stifel analyst Nathan Jones maintains Watts Water Technologies (NYSE:WTS) with a Hold and lowers the price target from $141 to $130.